Study Summary
To evaluate the safety and efficacy of autologous hematopoietic stem cell transplantation (ASCT) combined with BCMA-CART in the treatment of UHR-MM.
Want to learn more about this trial?
Request More InfoInterventions
BCMA CARTDRUG
Bcma-cart was reinfused at a dose of 1.0-2.0 × 10 \^ 6 / kg on day +3 (± 1 day) after autologous hematopoietic stem cell reinfusion.
Study Locations
| Facility | City | State | Country |
|---|---|---|---|
| Institute of Hematology & Blood Diseases Hospital | Tianjin | Tianjin Municipality | China |